Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing...
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heavily pretreated aggressive tumors, and who had all progressed on prior anti-PD-1 and chemotherapy, with 35% confirmed overall response rate (cORR), which is >2-fold higher than last prior line of therapy (15%) ...
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316 WATERTOWN, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Pr...
BRT Apartments Corp. Files Fourth Quarter and Full Year 2024 Financial Statements GREAT NECK, N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that it has filed its annual report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates, and, to a lesser extent, makes preferred equity investments in joint ventures ...
BRT Apartments Corp. Declares First Quarter 2025 Dividend and Announces Increase to Current Stock Repurchase Program GREAT NECK, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable April 4, 2025, to stockholders of record at the close of business on March 27, 2025. The Board of Directors also announced that it approved the extension of the Company’s share repurchase program through December 2026 and increased the value of the shares to be repurchased ...
America’s Car-Mart Reports Third Quarter Fiscal Year 2025 Results ROGERS, Ark., March 06, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the third quarter ended January 31, 2025. Third Quarter Key Highlights (FY’25 Q3 vs. FY’24 Q3, unless otherwise noted) Total revenue was $325.7 million, up 8.7%Sales volumes increased 13.2% to 13,198 unitsInterest income increased $3.0 million, up 5.1%Total collections increased 5.2% to $176.3 millionGross margin percentage increased 150 basis points to 35.7...
America’s Car-Mart, Inc. Announces Closing on Extension and Upsize of Its Revolving Credit Facility ROGERS, Ark., March 03, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today announced that it has extended and upsized its asset-based revolving credit facility (“ABL Facility”). The $350 million ABL Facility was upsized from the prior $320 million commitment and has been extended to mature on March 31, 2027. There was approximately $75 million drawn on the ABL Facility as of January 31, 2025. The ABL Facility was subscribed by a synd...
America’s Car-Mart, Inc. Schedules Third Quarter Fiscal Year 2025 Results and Conference Call ROGERS, Ark., Feb. 06, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2025 third quarter financial results on Thursday, March 6, 2025, before the market opens. President and Chief Executive Officer Doug Campbell and Chief Financial Officer Vickie Judy will host a conference call at 9:00 a.m ET to discuss the results. Participants may access the conference call via webcast using this link: . To participate via telephone, please register in ...
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with endometrial cancer and other tumor types Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient s...
America’s Car-Mart, Inc. Completes $200 Million Term Securitization Weighted average coupon improved 95 basis points from prior October 2024 securitization Transaction over 10 times oversubscribed ROGERS, Ark., Feb. 03, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), announced today that it has completed a term securitization transaction involving the issuance of $200 million in principal amount of asset-backed notes with an overall weighted average coupon of 6.49%. ACM Auto Trust 2025-1 issued $150.77 million of Class A Notes and $4...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.